Literature DB >> 22846125

Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.

Dáfne Cardoso Bourguignon da Silva1, Gláucia Toribio Finoti Seixas, Orlei Ribeiro de Araujo, Rodrigo Genaro Arduini, Fabianne Altruda de Moraes Costa Carlesse, Antonio Sergio Petrilli.   

Abstract

BACKGROUND: Usual treatment regimens with vancomycin often fail to provide adequate serum levels in patients with severe infections.
METHODS: Retrospective analysis of vancomycin trough serum measurements. The following parameters were calculated by Bayesian analysis: vancomycin clearance, distribution volume, and peak estimated concentrations. The area under the concentration curve (AUC) (total daily dose/24 h clearance of vancomycin) was used to determine the effectiveness of treatment through the ratio of AUC/minimum inhibitory concentration (MIC) above 400, using MIC=1 μg/mL, based on isolates of Staphylococci in cultures.
RESULTS: Sixty-one vancomycin trough measurements were analyzed in 31 patients. AUC/MIC>400 was obtained in 34 out of 61 dosages (55.7%), but the mean vancomycin dose required to achieve these levels was 81 mg/kg/day. In cases where the usual doses were administered (40-60 mg/kg/day), AUC/MIC>400 was obtained in nine out of 18 dosages (50%), in 13 patients. Trough serum concentrations above 15 mg/L presented a positive predictive value of 100% and a negative predictive value of 71% for AUC/MIC>400.
CONCLUSION: Higher than usual vancomycin doses may be required to treat staphylococcal infections in children with oncologic/hematologic diseases. Since the best known predictor of efficacy is the AUC/MIC ratio, serum trough concentrations must be analyzed in conjunction with MICs of prevalent Staphylococci and pharmacokinetic tools such as Bayesian analysis.
Copyright © 2012 Elsevier Editora Ltda. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846125     DOI: 10.1016/j.bjid.2012.06.011

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  15 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

2.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

3.  Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.

Authors:  Whitney R Buckel; Shahira Ghobrial; Pranita D Tamma; Aaron M Milstone; Yuan Zhao; Alice J Hsu
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

4.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

5.  Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function.

Authors:  Chanika Chuphan; Waroonrat Sukarnjanaset; Thanyawee Puthanakit; Thitima Wattanavijitkul
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

6.  The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.

Authors:  Theresa Madigan; Ronald M Sieve; Kevin K Graner; Ritu Banerjee
Journal:  Pharmacotherapy       Date:  2013-07-17       Impact factor: 4.705

7.  Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?

Authors:  Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock
Journal:  Pediatr Nephrol       Date:  2018-10-29       Impact factor: 3.714

Review 8.  The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.

Authors:  Stacey Tkachuk; Kyle Collins; Mary H H Ensom
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

9.  Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients.

Authors:  Hillary Orr; Deni Trone; Joshua Elder; Ashok Raj
Journal:  Children (Basel)       Date:  2017-08-28

10.  Reduced Vancomycin Susceptibility, MRSA and Treatment Failure in Pediatric Staphylococcus aureus Bloodstream Infections.

Authors:  Ethan Canty; Benjamin Carnahan; Tara Curley; Emily Anususinha; Rana F Hamdy; Jessica E Ericson
Journal:  Pediatr Infect Dis J       Date:  2021-05-01       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.